FDA panel doubts Sarepta has shown eteplirsen's efficacy

Members of FDA's Peripheral and Central Nervous System Drugs Advisory Committee voted 7-3 with three abstentions that clinical results provided by Sarepta Therapeutics Inc. (NASDAQ:SRPT) did not provide substantial evidence that eteplirsen ( AVI-4658) is effective to treat Duchenne muscular dystrophy (DMD).

Eteplirsen is under

Read the full 457 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE